To Get more Insights,  Request A Free Sample 

Where is the Future of the Hip Replacement Market Headed?

The trajectory is clear: the future of the hip replacement market is personalized, robotic, and digitally integrated. Robotic assistance is on track to be the norm of care with projections suggesting that it may be used for up to 70% of all hip and knee replacements in the U.S. by 2030. The use of AI in pre-operative planning is gaining prevalence, enabling surgeons to create an intricate blueprint for each patient, as it is unique for an individual. This integration of cutting-edge robotics, data-driven planning, advanced implant materials, is moving the market in a new era of highly customized solutions promising better longevity, and returning to an active life faster.

Robotics and Outpatient Surgery is the New Standard of Care

A profound operational shift is redefining the hip replacement market, with procedures increasingly migrating to outpatient settings powered by robotic technology. A bright catalyst to this move, as published by the Centers for Medicare & Medicaid Services (CMS), was the introduction of 11 new surgical codes to the Ambulatory Surgery Center list in 2024. As a result, the major operators are growing at an amazing rate. For example, Surgery Partners exploded from total knee replacement, but also USPI added 11 new ASCs in Q2 of 2024 including 3 high-volume centers which see over 15,000 cases per year.

This transition is facilitated by robotic platforms with sub millimeter level accuracy providing additional surgical accuracy. Leading this charge in the hip replacement market, Stryker announced its Mako system has been used in over 2 million procedures globally. The adoption of these technologies is hot, as Intuitive Surgical reports performing over 1.8 million da Vinci procedures a year across its installed base of over 8,000 systems across the world. To handle this expansion major operators of ASCs, such as USPI and Surgical Care Affiliates, administered roughly 520 and 320 centers respectively during 2024. The total number of Medicare certified ASCs has now grown to almost 6000 and we have a very good infrastructure for the new standard of care.

Evolving Patient Needs and sophisticated Materials are Powering Implant Evolution

Demand within the hip replacement market is also being shaped by an evolving patient demographic and a revolution in material science. The primary cause of hip failure, osteoarthritis causes a tremendous number with a recent analysis released in The Lancet reports that 595 million people are reported to live with the disease throughout the world in 2024. In the U.S. 58.5 million adults have some form of arthritis as reported by the CDC. Critically, this is not merely a condition of the elderly; an increasing number of hip replacements are now being carried out in people younger than 65 years of age, who have now greater expectations for longevity and performance of the implant.

To meet the needs of these younger, more active patients, implant technology is being made to progress at a rapid pace. The use of 3D printing for creating customized implants is becoming a key solution in the hip replacement market for solving complex primary hip replacement cases. For instance, surgeons are using custom 3D printed joints to re-create a patient's pelvis after widespread loss of a large amount of bone. In addition, advanced materials are prolonging implants. A large clinical study of Vitamin E-infused polyethylene liners to be released before the year 2025 showed significantly reduced rates of wear at the 10-year mark. The fact we saw in real life is quite apparent, therefore, just by revision incidence for these advanced linings eg one report from last year revised in extent at 2.3% only in 2024. Such innovations are indispensable especially when infection is one of the main areas of concern, with 26.3% of all revision surgeries due to infection by 2023.

Segmental Analysis 

Total Hip Replacement Enjoy Prime Position in Global Market

Total hip replacement surgery unquestionably stands as the leading procedure within the broader hip replacement market, a dominance supported by a remarkable volume of successful operations. For example, the 2024 report by the American Joint Replacement Registry analyzed more than 4.3 million procedures and found that the percentage of HA or primary total hip arthroplasty (in-or referred to as THA) represented a large percentage of 32.4% of the performed surgeries in 2023. This preference is also reflected in surgical practice with the average surgeon undertaking 44.3 elective primary THAs that year. Consequently, there is a huge demand which presents severe logistical challenges to healthcare systems.

Despite an 18% surge in hip replacement procedures in Canada hip replacement market between 2019 and 2023, only 66% of patients were able to receive their surgery within the recommended 26-week window. This backlog points out the sustained and increasing need for this life enhancing procedure. Furthermore, the waiting lists are also a good tale to tell; in early 2025, Canada patients have experienced an average wait of 30.3 weeks. A similar situation exists in Ireland with 105 patients at a single major orthopedic hospital having to wait 6-12 months as of September 2024. While some studies have revealed that hemiarthroplasty has lower readmission rates in certain geriatric cases of a broken bone, the totality of benefits of a total hip replacement make it the long-term solution of choice.

• In 2023 the average surgeon will have worked out almost one primary total hip replacement per week.
• A total and partial hip replacement had almost the same need for a second surgery rotation within two years, as it was shown in a multinational study.
• The longest-waiting 10% of patients in some areas of Canada had a wait time of around 44.4 weeks for the procedure done in early 2025.

Proven Durability Metal-on-Polyethylene's Leadership with Hip Implants

Within the dynamic hip replacement market, the metal-on-polyethylene combination remains the material of choice, a leadership position justified by its market penetration and proven clinical performance. In 2024, these bearings were on the impressive side of the sales with 46.53% of the total hip replacement sales saying that products available from them are trusted by surgeons and healthcare providers. In addition, while ceramic-on-polyethylene has become the most common bearing for elective primary procedures, comprising 73.5% of all cases in 2023, there is in unfamiliar cases of metal head-on-highly cross-linked polyethylene or polyethylene (HXLPE), ensuring that it remains relevant and cost effective.

The exceptional durability of HXLPE is a primary reason for its widespread use across the global hip replacement market. A 2025 study focused instead on younger patients under age 30, and the resilience to a bearing's wear rate comes at about 20.8 mm3/yr, demonstrating the volume wear rate of a bearing with natural high wear demands due to being more active patients. Further reinforcing this a third generation HXLPE liner with a ten year analysis showed an even more reduced mean linear wear rate of just 0.0172 mm/year. The success of any hip replacement over the long term falls on such material innovations. Specific implant trials corroborate these figures, with one randomized study observing a wear rate of only 0.01 mm/yr for a 28 mm metal-on-XLPE articulation which sealed its legacy for wear longevity.

• Despite the advent of ceramics, metal-on-polyethylene still captures almost half of the market share of implant materials.
• Even in the most active young patients, first-generation advanced polyethylene has a wear rate which is measured in tiny fractions of a millimeter per year.
• A long-term study after a certain cross-linked polyethylene liner for more than 10 years provided an average wear of only 0.03 mm per year.

Hospitals Continue to Provide the Foundation for Delivery of Hip Replacement Surgery

Hospitals continue to be the dominant end-user in the hip replacement market, serving as the central hub for the vast majority of surgical procedures and post-operative care. As compared to 2024, an overwhelming 71.42 percent of all hip replacement surgeries were performed in a hospital setting. The United States alone has about 6,093 hospitals with the Newsweek in 2025 recognizing 175 such hospitals for their excellence in orthopedics. In addition, hospitals have gotten highly efficient with single bed days; the length of stay for a primary total hip arthroplasty in the U.S. in 2023 was helpfully 1.1 days with 92% of patients being guided straight home.

While hospitals firmly hold their leading position, the hip replacement market is witnessing a notable evolution with the expansion of Ambulatory Surgery Centers (ASCs). The number of surgeries using total implantation of hip arthroplasty (ASC) in the market grew by 34% in 2023 alone. By the end of that year these outpatient centers were conducting a total of 62,110 total joint procedures, an increase of 70% over 2022. Nevertheless, hospitals are a must in the management of complex cases and post-surgical problems. For example, readmission rates within 3 months were 8% at one major Irish university hospital in 2021 and readmission rates of near 6.9% of patients discharged to specialized care facilities after their hip replacement were noted in another study.

• In 2023, over nine in 10 primary hip replacement patients in US went directly home from hospital.
• The number of joint replacements performed in outpatient surgery experience centers rose dramatically by 70% in one year.
• A comprehensive study found that more than 81% of patients were discharged from the hospital within two weeks of them having their surgery.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America Dominance Is Driven By Technology and High Surgical Volumes

North America commands the hip replacement market with a formidable 41.33% share, driven by high procedural volumes and rapid technological adoption in the United States. In 2024, there were more than 35,000 members who formed a massive network to be specialists, according to the American Academy of Orthopaedic Surgeons. The US is expected to conduct 652,000 total hip arthroplasty in 2025 alone. One of the largest hospital-related healthcare organizations, HCA Healthcare, conducted 58,000 joint replacement surgeries on inpatients in 2024. The volume infrastructure to support is huge; there are about 6000 Medicare-certified Ambulatory Surgery Centers active in 2024. In Canada, more than 65,000 hip replacement surgeries were performed last year, as reported in Statistics Canada by the Canadian institute for healthcare Information.

The region's leadership in the hip replacement market is also cemented by its embrace of advanced technology. There are over 2,500 companies of orthopedic medical devices leading the innovation in the U.S. The installed base of robotic systems is envisioning from the 1500+ Mako systems in the US from the beginning of 2024. Access is, however, a challenge in some areas. For example, the waiting list to have a hip replacement in Ontario, Canada, in 2024 was just 190 days for the median. This is a further testament to the demand, as the incidence of related injuries is high, with more than 300,000 older adults being hospitalized with hip fractures every year in the U.S. according to the CDC.

The Established Registries and Healthcare Systems in Europe Are the Primary Driving Forces for the Steady Demand of the Market

Europe's mature hip replacement market is characterized by robust national healthcare systems and comprehensive joint registries that ensure high standards of care. In the UK more than 100,000 hip replacement operations are performed by the National Health Service (NHS) annually. A crucial resource in the UK is the National Joint Registry that held information of more than 1.6 million main hip replacement procedures by 2024. Germany also shows particularly high surgical volumes with some 240,000 hip replacement procedures per year. In Sweden, a registry known as the Swedish Hip Arthroplasty Register has been used to track almost 2 million procedures since it began.

This can be a problem despite the high volumes patient access can be strained. In England, the waiting list for trauma and orthopedic treatment in the NHS had more than 800,000 patients in early 2024. The regional hip replacement market's surgical workforce is substantial; Germany has over 8,000 orthopedic and trauma surgeons. As a method of better care, there are over 1,400 public hospitals in France that are equipped to carry out major surgeries. The region is also burdened by many fractures with osteoporosis, such as more than half a million barriers in Germany in 2024. There are 110 hospitals doing joint replacements in the Netherlands.

Asia Pacific Emerges as the Fastest Growing Hip Replacement Market Hub

The Asia Pacific region is rapidly becoming a center for growth in the hip replacement market, propelled by expanding healthcare infrastructure and a growing elderly population. Australia stampers with a highly developed market with its national joint replacement registry reporting more than 52,000 hip replacement procedures in the most recent annual report. Japan's super-aged population, which will count more than 36 million patients aged 65 and older in 2024, provides for a significant market of patients. The Japanese Orthopaedic Association has more than 25,000 members who serve this population. In India, the number of orthopaedics has exceeded 20000.

The region's growth in the global hip replacement market is supported by a burgeoning medical device industry and investment in specialized facilities. Currently, there are more than 2000 domestic orthopedic implant manufacturers in China. India has witnessed the growth of more than 200 individual orthopedic specialty hospitals to capitalize the growing demand. Furthermore, the number of robotic surgical systems in China has more than 360 units in early 2024. Medical tourism is a factor too as countries such as Thailand conduct thousands of joint replacements for foreigners each year. In South Korea, the National Health Insurance Service funds more than 30,000 hip replacement procedures a year.

Recent Developments in Hip Replacement Market 

• Enovis Finalizes Transformative Acquisition of LimaCorporate S.p.A.: This move significantly expands the global reach and reconstructive portfolio of Enovis, boosting its international presence.
• Stryker Completes Acquisition of French Joint Replacement Leader SERF SAS: The deal strengthens Stryker's joint replacement offerings and footprint across Europe, particularly in the French market.
• Zimmer Biomet Acquires Commercial Assets from OSSIS for Patient-Specific Implants: This acquisition enhances ZB's capabilities in providing 3D-printed, patient-specific implants to the Asia Pacific region.
• CurvaFix Secures USD 39 Million in New Financing for Fracture Repair System: These funds will accelerate the U.S. commercialization of its unique, patented system for repairing pelvic fractures.
• OrthoPediatrics Corp. Acquires Boston Orthotics & Prosthetics for USD 22 Million: This acquisition in the hip replacement market expands the company's specialty bracing portfolio and broadens its reach into the pediatric orthotics market.
• Bioventus Completes Acquisition of CartiHeal for Cartilage Regeneration Tech: This deal adds a novel cartilage and bone regeneration device for knee injuries to the Bioventus portfolio.
• Zimmer Biomet enters into agreement to distribute Think Surgical's Robotic Business: This strategic move bolsters the company’s robotic surgery offerings with a focus on hip and knee replacement systems.

Top Companies in the Hip Replacement Market

• Arthrex
• B. Braun SE
• Bioimpianti
• Conformis
• Corin Group
• Enovis (DJO Global)
• Exactech Inc.
• Globus Medical
• Integra LifeSciences
• Johnson & Johnson (DePuy Synthes)
• JRI Orthopaedics
• LimaCorporate
• Mathys Ltd Bettlach
• Medacta Group
• MicroPort Scientific Corporation
• Smith & Nephew plc
• Stryker Corporation
• United Orthopedic
• Wright Medical Group N.V.
• Zimmer Biomet
• Other Prominent Players

Market Segmentation Overview

By Procedure

• Primary hip reconstruction devices
  • Cemented primary hip reconstruction surgeries
  • Cementless primary hip reconstruction surgeries
• Partial hip reconstruction surgeries
  • Cemented partial hip
  • Cementless partial hip
• Hip resurfacing surgeries
• Revision hip reconstruction
• Total replacement

By Material

• Metal-on-metal
• Metal-on-polyethylene
• Ceramic-on-polyethylene
• Ceramic-on-metal
• Ceramic-on-ceramic

By End User

• Hospitals
• Speciality Clinics
• Ambulatory Surgery Centres

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America